Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
| End Date: | August 2011 |
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic
study.
This is a study of PEGPH20 in human subjects and is designed to evaluate the safety of
PEGPH20 and to determine the maximum tolerated dose of PEGPH20. All patients will receive
PEGPH20. Each group of patients will receive a higher dose than the previous group. This
will continue until the group with the highest planned dose completes the study or until a
group has major side effects from their assigned dose.
We found this trial at
4
sites
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials